Stockscreener 앱 받기
36.21
0.44%
-0.1581
전일 마감가:
$36.37
열려 있는:
$36.33
하루 거래량:
506.03K
Relative Volume:
0.79
시가총액:
$2.54B
수익:
-
순이익/손실:
$-195.21M
주가수익비율:
-11.40
EPS:
-3.1763
순현금흐름:
$-176.19M
1주 성능:
-6.82%
1개월 성능:
-0.17%
6개월 성능:
+39.27%
1년 성능:
+42.78%
1일 변동 폭
$35.50
$36.88
1주일 범위
$35.50
$40.00
52주 변동 폭
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
36.17 | 2.67B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
511.70 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.32 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.83 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
991.23 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.09 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-09 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $62. - GuruFocus
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win - Seeking Alpha
Pharvaris stock gets $60 target at H.C. Wainwright on trial data By Investing.com - Investing.com South Africa
Pharvaris N.V. Designates Leiden Office as Principal Executive Location Amid Deucrictibant Development Risks (NASDAQ: PHVS) - Kalkine Media
Pharvaris preps for MAA on deucrictibant data for HAE - BioWorld News
Pharvaris President Lu Peng Executes 15,000 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
PHVS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
Wells Fargo raises Pharvaris stock price target on strong trial data By Investing.com - Investing.com South Africa
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy - AllSci
RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens raises Pharvaris stock price target to $79 on HAE therapy - Investing.com Nigeria
Insider at Pharvaris (PHVS) lines up new stock sale - Stock Titan
Pharvaris N.V. (PHVS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why is Pharvaris stock surging today? By Investing.com - Investing.com Nigeria
Pharvaris N.V. - Reuters
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is Pharvaris stock surging today? - investing.com
Why Is Pharvaris Stock Soaring Tuesday? - Benzinga
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones - TipRanks
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Rare swelling attacks plunge in Pharvaris (PHVS) pill trial, with key U.S. drug decisions slated for 2027. - Stock Titan
Pharvaris stock surges 27% on positive trial data By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pharvaris reports positive phase 3 results for HAE drug By Investing.com - Investing.com Nigeria
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ) - Seeking Alpha
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR - TipRanks
Pharvaris stock surges 27% on positive trial data - investing.com
Pharvaris reports positive phase 3 results for HAE drug - Investing.com
Pharvaris Announces Positive Topline Data from CHAPTER-3 - GlobeNewswire
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Pulls Back 4.5% to $35.32 as Shares Approach Key SupportFibonacci Time Zone - vinanet.vn
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighWhat's Next? - MarketBeat
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.38%
2.06%
자본화:
|
볼륨(24시간):